ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Glaukos and Huons Global side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

GlaukosHuons Global
studies on the registry6733
open to participants now147
phase 3 studies under way24
reach primary completion within a year45
programswith a study of their own in two years58

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseGlaukosHuons Global
Phase 100%

Huons Global: 4 of its 8 programs at phase 1

  1. Atorvastatinphase 1
  2. HUC2-676phase 1
  3. Pitavastatin plus Ezetemibephase 1
  4. Telmisartanphase 1
50%
Phase 2

Glaukos: 2 of its 5 programs at phase 2

  1. GLK-221phase 2
  2. GLK-321phase 2
40%

Huons Global: 1 of its 8 programs at phase 2

  1. HUC1-394phase 2
13%
Phase 3

Glaukos: 1 of its 5 programs at phase 3

  1. Gen 2 Travoprost Intracameral Implantphase 3
20%

Huons Global: 3 of its 8 programs at phase 3

  1. HU-045phase 3
  2. HUC3-637phase 3
  3. HUC3-637-Rphase 3
38%
Approved, new studies

Glaukos: 2 of its 5 programs at approved, new studies

  1. Travoprostapproved, new study
  2. Riboflavin Ophthalmic Solutionsapproved, new study
40%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Glaukos2 readouts · 1 phase 3·····

Glaukos, Apr ’27: 1 program whose next study reaches primary completion

  1. GLK-221phase 2 · Apr 0 · NCT07400952
····

Glaukos, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Riboflavin Ophthalmic Solutionsapproved, new study · Sep 0 · NCT07629557
·
Huons Global5 readouts · 1 phase 3···

Huons Global, Feb ’27: 1 program whose next study reaches primary completion

  1. Pitavastatin plus Ezetemibephase 1 · Feb 0 · NCT07784621
·

Huons Global, Apr ’27: 2 programs whose next study reaches primary completion

  1. Atorvastatinphase 1 · Apr 0 · NCT07784608
  2. Telmisartanphase 1 · Apr 0 · NCT07784608

Huons Global, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. HU-045phase 3 · May 0 · NCT07870694

Huons Global, Jun ’27: 1 program whose next study reaches primary completion

  1. HUC1-394phase 2 · Jun 0 · NCT07656688
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Glaukos

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Huons Global

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionGlaukosHuons Global
Glaucoma, Open-Angleboth · compare here

Glaukos in Glaucoma, Open-Angle: 1 program

  1. Travoprostapproved, new study

Their studies: Glaukos’ studies of Glaucoma, Open-Angle in search

Huons Global in Glaucoma, Open-Angle: 2 programs

  1. HUC3-637phase 3
  2. HUC3-637-Rphase 3

Their studies: Huons Global’s studies of Glaucoma, Open-Angle in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Glaukos 1 of 5 · Huons Global 2 of 8 programs (3 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.